Navigation Links
'Clot-Buster' Drug May Still Be Best Stroke Treatment
Date:2/6/2013

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Feb. 6 (HealthDay News) -- The standard medical care for patients having an ischemic stroke is to give powerful "clot-busting" drugs as soon as possible after the start of the stroke.

But some hospitals are starting to rely on new treatment methods that actually go into the artery and retrieve the clot or destroy it at the site.

According to a new study from Italy, however, these new methods -- collectively referred to as endovascular treatment -- are no better than the standard clot-buster drug known as tissue plasminogen activator (tPA).

"Our findings do not provide support for the use of the more invasive and expensive endovascular therapy over intravenous treatment," said study author Dr. Alfonso Ciccone, director of the stroke unit and neurology department at Carlo Poma Hospital, in Mantua.

The results indicate that standard, intravenous tPA is the first-line therapy for acute stroke, he said.

"This defines a clear priority in treatment options," said Ciccone, who coordinated the study while working at Niguarda Ca Granda Hospital, in Milan.

The study appeared online Feb. 6 in the New England Journal of Medicine, to coincide with a presentation at the American Stroke Association annual meeting, in Honolulu.

Ischemic strokes account for 87 percent of all strokes and are caused by a blockage in one of the blood vessels carrying blood to the brain. (Most other strokes are hemorrhagic, which result when a blood vessel breaks, leaking blood into the brain.)

Studies have shown that administering tPA through an IV line within 4.5 hours of the onset of the ischemic stroke can greatly minimize damage to the brain and this is now widely viewed as the standard of care for this type of stroke, said Dr. Curtis Benesch, medical director of the Stroke and Cerebrovascular Center at the University of Rochester Medical Center, in New York.

But endovascular strategies have shown a better rate of "recanalization," or opening the artery up, Benesch said.

"The difficult challenge has been trying to establish that recanalization is clearly associated with improved clinical outcome," he added.

For this study, Ciccone and his colleagues randomly assigned 362 patients with acute ischemic stroke to undergo endovascular therapy or standard tPA administered intravenously.

Endovascular therapy given in the study included administering tPA through the artery directly into the clot or retrieving or breaking up the clot mechanically, or a combination of both.

All treatments occurred with 4.5 hours of the beginning of the stroke.

After three months, about a third of patients in each group were alive and without disability. In other words, there was no difference in outcomes.

A number of reasons might account for the results, including the extra time it takes to perform endovascular therapy, said Dr. Daniel Labovitz, director of the Stern Stroke Center at Montefiore Medical Center, in New York City.

In this study, endovascular treatment delayed initiation of treatment by one hour, study author Ciccone said.

But another explanation for the finding is possible and may be good reason not to write off endovascular strategies entirely, experts said.

In particular, devices called stent retrievers "seem to be more effective and safe than their predecessors," Ciccone said. But they are so new that they were only used in the last phase of this study, which ran from 2008 through 2012.

"We do not know if the extensive use of these devices could have produced more favorable results for endovascular therapy," Ciccone said.

For his part, Labovitz said that stent retrievers "have been a game changer."

It's also possible that different patients would benefit from different treatments but doctors don't yet know which patients fall into which group, Labovitz said.

"Treatment is evolving so rapidly," Labovitz said. "I think this is why getting negative results isn't making any of us lose hope."

Benesch agreed that the new finding shouldn't be taken as the final word.

"Many people are going to view [the current study] as a lack of support for endovascular treatment, saying all the excitement and enthusiasm isn't warranted . . . but I think that's a bit shortsighted," Benesch said.

More information

The American Heart Association has more on ischemic strokes.

SOURCES: Alfonso Ciccone, M.D., director, department of neurology and stroke unit, Carlo Poma Hospital, Mantua, Italy; Daniel Labovitz, M.D., director, Stern Stroke Center, Montefiore Medical Center, New York City; Curtis Benesch, M.D., medical director, Stroke and Cerebrovascular Center, University of Rochester Medical Center, Rochester, N.Y.; Feb. 6, 2013, presentation, American Stroke Association annual meeting, Honolulu; Feb. 6, 2013, New England Journal of Medicine, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Flu Still Widespread but Easing in Some States: CDC
2. Certain Jobs May Still Pose Risk for Asthma
3. Smoking Still Takes a Heavy Toll in U.S., CDC Finds
4. Flu Still at Epidemic Levels: CDC
5. Use of anti-depressants during pregnancy not linked with increased risk of stillbirth, infant death
6. Millions of patients still waiting for medical breakthroughs against neglected diseases
7. Unlocking the genetic mysteries behind stillbirth
8. Racial Disparities Still Seen in Use of Breast Cancer Treatments
9. Despite FDA Warning, Sports Supplements Still Available Online: Study
10. Analysis of conflicting fish oil studies finds that omega-3 fatty acids still matter
11. Discontinued Meds May Still Get Dispensed
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Clot-Buster' Drug May Still Be Best Stroke Treatment 
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on ... later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his ... the hospital’s 30th heart transplant recipient. , “He was playing at home, when we ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... AlignLife clinics nationwide ... Many children are not fortunate enough to receive bountiful gifts wrapped tightly under a ... can bring to the children of the world. , In exchange for generous donations, ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Research and Markets has announced the addition of the ... to 2021" report to their offering. ... , , The immunohistochemistry (IHC) ... a CAGR of 7.3% during the forecast period of 2016 to 2021. ... rapidly increasing geriatric population across the globe are the primary driving the ...
(Date:12/7/2016)... 7, 2016  Palatin Technologies, Inc. ("Palatin") (NYSE ... a previously disclosed underwritten public offering of units ... as sole book-running manager, Roth Capital Partners acted ... as co-manager for the offering. "This ... net proceeds, allowing us to continue advancing bremelanotide ...
(Date:12/7/2016)... , Dec. 7, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Janus Kinase 3 (JAK3) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
Breaking Medicine Technology: